Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insulin The Focus At ADA 2012, But Don’t Forget GLP-1s And SGLT-2s

This article was originally published in The Pink Sheet Daily

Executive Summary

In anticipation of the American Diabetes Conference of 2012, analysts take a look at several categories of drugs that will be playing a major role in the future of diabetes care.

You may also be interested in...



Ember Therapeutics Angles For Lead In ‘Brown Fat’ Therapeutics

Ember’s co-founder Bruce Spiegelman explained in the Banting Lecture at the American Diabetes Association earlier in June how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of ‘brown’ fat.

“Brown Fat” Attracts Start-Up Interest, Highlighted At ADA 2012

Bruce Spiegelman, co-founder of the start-up Ember Therapeutics and winner of ADA’s prestigious Banting Award, described how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of “brown” fat.

New Long-Acting Insulin Offerings Could Derail Lantus Franchise

Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel